Patients who require rhythmic assistance in two chambers of the heart now have the option of a leadless system, after the US Food and Drug Administration (FDA) approved Abbott’s AVEIR dual-chamber (DR) leadless pacemaker system.
The FDA nod came hot on the heels of clinical data announced by the medical device giant in May, demonstrating that 97% of participants had successful atrioventricular (AV) synchrony following device implant.
